Purpose: Despite a high cure rate of approximately 85% in Wilms' tumor by multimodality therapy, to date only four drugs are known to be active against such tumors. There is a clear need for new active drugs.
courses of etoposide, the second course being administered at day 21.
Results: A complete response (CR) was documented in two patients, partial response (PR) in 11, stable disease in 10, and progressive disease (PD) in eight. The duration of response could not be evaluated, because all responding patients were subsequently treated with multimodality therapy. The major toxicities observed were neutropenia and thrombocytopenia, but most patients had been heavily pretreated. No toxic death clearly associated with etoposide was noted.
Conclusion: It is concluded that etoposide in this schedule is an active agent in Wilms' tumor and should be considered for inclusion in regimens for high-risk patients, such as those with metastatic disease at diagnosis and those who relapse after multiagent chemotherapy.
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to the inhibition of the enzyme topoisomerase II. Its doselimiting toxic effect is myelotoxicity. Although widely used in many regimens for various diseases, there are few large single-agent phase II studies in pediatric tumors. Activity has been reported with both teniposide and etoposide in previous small studies'' 3 ; in the only phase II study reported by Kung et al, 4 no response was seen among 11 patients with Wilms' tumors treated with a twice-lower dose of etoposide (150 mg/m2/d X 3 consecutive days every 3 weeks).
Noting the SFOP experience of an impressive activity of high-dose ifosfamide in relapsed Wilms' tumors (despite the poor efficacy of conventional doses of cyclophosphamide), we conducted a new phase II trial using high-dose etoposide (1 g/m2).
PATIENTS AND METHODS
From June 1986 to April 1990, 31 patients (Table 1) with refractory or relapsed Wilms' tumor were entered onto the study by 14 French and three British centers. Histology was unfavorable in four cases (two anaplastic and two clear-cell sarcoma). There were 22 females and nine males. The mean age was 6.7 years (range, I to 20). The patients had previously been treated according to the protocols of the SIOP or the United Kingdom Children's Cancer Study Group (UKCCSG).
Initial stage according to the SIOP system 5 was I in three patients, 11 in seven (with positive lymph nodes in one), III in nine, IV in 10, and V in two. Prior chemotherapy, administered initially or at relapse, included vincristine and dactinomycin in all cases, doxorubicin or epirubicin in 30, and ifosfamide in 20. The sites of relapse or resistant disease were lung alone in 13 patients, abdomen or pelvis in six patients, liver in one patient, and multiple in 11 patients, including lungs (n = 9), abdomen or pelvis (n = 8), liver (n = 5), nodes (n = 3), bone (n = 1), and subcutaneous (n = 1).
When entered onto the study, 12 patients were in first relapse, 10 in second relapse, four in third or more relapse, and five had never achieved a complete remission.
Etoposide was infused intravenously (IV) over 1 to 2 hours at a dose of 200 mg/m 2 over 5 consecutive days every 21 days. The majority of children were treated as outpatients. No treatment had been received for at least 3 weeks before the beginning of the study. A WBC count was performed 7 to 14 days after treatment in the event of fever, and at 21 days before the next course of etoposide. Except for those patients (n = 2) whose disease progressed after the first course, all underwent at least two courses of therapy and were evaluated after the second course. After the first course, the following courses were delayed if the WBC count was less than 2.0 x 10 9 /L, neutrophils less than 1.0 10 9 /L, or platelets less than 100 X 10 9 /L.
Measurable disease assessed by radiologic and/or ultrasound examinations had to be documented before entry onto the study. Response was evaluated at day 42 (or 21 days after the second course) and defined according to World Health Organization (WHO) criteria as reported by Miller et a16 in 1981 and based on two-dimensional measurements. After evaluation, treatment in responding patients consisted of surgery, irradiation, and/or the continuation of the chemotherapy with etoposide alone or in combination with other drugs. Some patients were also treated with high-dose consolidation chemotherapy followed by autologous bone marrow transplantation (ABMT).
RESULTS
Two patients received only one course of therapy because of progressive disease (PD). Of the remaining patients, 19 received two courses, six received three courses, two received four courses, and two received five courses. PD occurred in eight patients, no response (NR) in 10, partial response (PR) in 11, and complete response (CR) in two. The duration of response to etoposide alone more than 1 month after evaluation could not be determined because all of the responding patients were subsequently treated with multimodality therapy. Of the patients who achieved CR, one received bilateral lung irradiation and was still alive in CR 48 months later without any further therapy; the second patient relapsed 11 months later despite highdose chemotherapy that included etoposide, carboplatin, and melphalan followed by ABMT. Among the 11 PRs observed, the median duration of the progression-free interval was 8 months. With subsequent therapy, four complete remissions were achieved, but three of these patients relapsed again. None of the five patients with NR at the time of evaluation (after two courses) underwent any objective response after subsequent courses of etoposide.
Toxicity
Toxicity was reported according to the WHO recommendations for grading of acute and subacute toxicity reported by Miller et al. 6 Hematologic toxicity was documented in 24 of 31 patients during at least one of two courses. The major toxicity observed was neutropenia, which was grade IV in 17 patients, grade III in four, grades I or II in two, and not documented in eight. Eleven patients were documented to have at least one episode of grade IV thrombocytopenia. Grade III anemia occurred in six patients and required transfusion. Fever, mainly of unknown origin, occurred in 17 patients during neutropenia. One fungal infection was seen (Torulopsis glabrata), as well as one varicella and one urinary tract infection. Oral mucositis was mild, even in neutropenic patients, and was grade II or more in only three patients. No toxic death clearly related to etoposide occurred. One patient with a PR after etoposide died 7 months later of renal dysfunction with Fanconi syndrome. He had previously received ifosfamide and had achieved a CR after high-dose chemotherapy and ABMT.
DISCUSSION
These data demonstrate that I g/m 2 etoposide administered parenterally over a 5-day period is an effective agent in relapsed Wilms' tumor. Twenty of 31 patients were heavily pretreated, having received the four most active agents in this disease, namely, vincristine, dactinomycin, doxorubicin, and ifosfamide. Within this group there were six responses (30%). There were seven responders (63%) among 11 relapsed patients who had not received ifosfamide as part of either first-or second-line therapy. Treatment was well tolerated and, considering that the total dose per course of etoposide was high (1 g/m 2 ), severe myelosuppression in such heavily pretreated patients was to be expected. Salvage rates in children with relapsed Wilms' tumor were recently reviewed in series conducted in the United States and United Kingdom. 7 8 In the National Wilms'
Tumor Study study, six favorable prognostic factors emerged: initial favorable histology, initial stage I, no prior irradiation, only two drugs administered, relapse limited to lungs, and, finally, recurrence more than 12 months after diagnosis. This study suggested that salvage therapy could still be effective in many patients using doxorubicin and dactinomycin with radiotherapy as appropriate. Such was not the case in the United Kingdom series, in which even in patients with relapsed stage I disease who had been treated with single-agent therapy, only half achieved a long-term second remission. There were few long-term survivors among those who relapsed after more advanced initial disease, despite aggressive multiagent chemotherapy.
The most active new agent recently explored in Wilms' tumor is ifosfamide, which, in both a United Kingdom series and the French SFOP study, has shown an encouraging response rate.' 9 However, this drug has major undesirable side effects in uninephric patients. Although some degree of renal tubular toxicity may be acceptable in high-risk sarcoma patients, in Wilms' tumor patients, in whom long-term survival is common even in those with metastatic disease, it is becoming apparent that ifosfamide should probably be avoided. If an alkylating agent may play a role in Wilms' tumor therapy, it would be interesting to test the efficacy of high-dose cyclophosphamide as more appropriate in terms of late sequelae. There are a few studies of cisplatin in Wilms' tumor, but the results have been disappointing.'" The comparatively nontoxic cisplatin analog carboplatin is currently under evaluation by the New Agents Group of the UKCCSG. Moreover, concerning anthracycline therapy, there have recently been reports of significant cardiac dysfunction in children given what was previously considered a safe dose of doxorubicin or daunorubicin."'12 Although analogs such as epirubicin may be slightly less cardiotoxic, ideally this group of drugs should be avoided, if possible, in curable tumors.
Unfortunately, as with most effective chemotherapy agents, etoposide may have its own late sequelae. Recently, concern has been expressed about the potential carcinogenicity of epipodophyllotoxins, with reports of secondary leukemia both in children with T-cell leukemia who received teniposide and in adults with malignant germ cell tumor who received etoposide.13"14 However, in these pa-tients, the total dose of epipodophyllotoxin was high, and it seems likely that this adverse effect is, in part, dose-related. A more recent report by Pui et al" 5 also emphasized the key role of the schedule of epipodophyllotoxin administration, rather than the cumulative dose, in secondary acute myeloid leukemia related to prolonged therapy with epipodophyllotoxin derivates in children.
Because of the short duration of therapy for children with Wilms' tumor, secondary acute myeloid leukemia due to etoposide exposure appears to be an unlikely consequence, no greater than that associated with the use of cyclophosphamide or ifosfamide. Until the precise risk factors involved in the association between secondary leukemia and epipodophyllotoxins are clarified, it would seem appropriate to limit the use of etoposide to initially metastatic or relapsed patients.
In summary, the response rate reported here should encourage clinicians to include etoposide in the initial treatment of patients with metastatic disease. The high dose of etoposide would probably necessitate an alternating two-drug schedule of etoposide combined with dactinomycin or doxorubicin. This would involve a reduction in the dose-intensity of these active agents, which might be offset by the additional efficacy of etoposide. A randomized comparison of etoposide versus doxorubicin in metastatic and other nonlocalized disease should also be considered, perhaps with a lower dose of etoposide.
